<DOC>
	<DOCNO>NCT00412529</DOCNO>
	<brief_summary>This exploratory study design determine early viral kinetic profile treatment telbivudine entecavir multiple time point 12 week .</brief_summary>
	<brief_title>Viral Kinetics Study Telbivudine Entecavir Adults With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Male female , 1870 year age document compensated hepatitis B `` e '' antigen ( HBeAg ) positive chronic hepatitis B Able comply study regimen provide write informed consent Pregnant breastfeeding Unwilling use double barrier method contraception Coinfected hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) human immunodeficiency virus ( HIV ) Received Hepatitis B therapy past Use immunomodulatory therapy past 12 month History symptom hepatic decompensation pancreatitis Frequent prolong use potentially hepatotoxic nephrotoxic drug Concurrent medication likely preclude compliance schedule evaluation Use investigational drug within 30 day enrollment Abnormal laboratory value screen Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HBeAg-positive , chronic hepatitis B</keyword>
	<keyword>telbivudine</keyword>
	<keyword>entecavir</keyword>
	<keyword>viral kinetics</keyword>
</DOC>